BSG and cancer: Particularly, MCT1 (SCL16A1) and MCT4 (SCL16A3), both chaperoned by CD147, are strongly associated with cancer aggressiveness, as they were found to be overexpressed in multiple cancers, also correlating with therapy resistance [23,24,25].